Characterization of the different BCR-ABL transcripts with a single multiplex RT-PCR.

Area of Science:

• Molecular Biology
• Hematology
• Oncology

Background:

• Chronic myeloid leukemia (CML) diagnosis relies on Philadelphia chromosome or BCR-ABL gene detection.
• BCR-ABL transcript variants (p190, p210, p230) are crucial for clinical trial patient stratification.
• Existing diagnostic kits often fail to detect p230 transcripts and exotic breakpoints.

Purpose of the Study:

• To develop a comprehensive molecular diagnostic assay for all BCR-ABL transcripts.
• To simultaneously characterize all possible BCR-ABL transcript junctions in a single assay.
• To improve CML patient classification for clinical trials.

Main Methods:

• Reverse Transcription Polymerase Chain Reaction (RT-PCR) using specific BCR primers and a common ABL primer.
• RT-PCR performed with different fluorochrome-coupled BCR primers tailored to specific transcripts.
• PCR-capillary electrophoresis for simultaneous transcript and junction identification via fluorescence detection.

Main Results:

• The developed assay successfully identifies all BCR-ABL transcripts, including p190, p210, and p230 variants.
• The assay accurately characterizes all possible BCR-ABL transcript junctions.
• Simultaneous identification of transcript type and junction is achieved in a single assay.

Conclusions:

• The novel RT-PCR and capillary electrophoresis assay provides a complete molecular diagnosis for CML.
• This assay overcomes limitations of current kits by detecting all BCR-ABL transcripts and junctions.
• Enhanced diagnostic capabilities will facilitate more precise patient stratification in CML clinical trials.